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Abstract
BCG has been administered globally for more than 75 years, yet tuberculosis (TB) continues to kill more than 2 million
people annually. Further, BCG protects childhood TB but is quite inefficient in adults. This indicates that BCG fails to induce
long-term protection. Hence there is a need to explore alternative vaccination strategies that can stimulate enduring T cell
memory response. Dendritic cell based vaccination has attained extensive popularity following their success in various
malignancies. In our previous study, we have established a novel and unique vaccination strategy against Mycobacterium
tuberculosis (M. tb) and Salmonella typhimurium by utilizing infected macrophages (IM). In short-term experiments (30 days),
substantial degree of protection was observed. However, remarkable difference was not observed in long-term studies (240
days) due to failure of the vaccine to generate long-lasting memory T cells. Hence, in the present study we employed T cell
memory augmenting cytokines IL-1+IL-6+TNF-a and IL-7+IL-15 for the induction of the enhancement of long-term
protection by the vaccine. We co-administered the M. tb infected macrophages vaccine with IL-1+IL-6+TNF-a (IM-1.6.a) and
IL-7+IL-15 (IM-7.15). The mice were then rested for a reasonably large period (240 days) to study the bona fide T cell memory
response before exposing them to aerosolized M. tb. IM-1.6.a but not IM-7.15 significantly improved memory T cell response
against M. tb, as evidenced by recall responses of memory T cells, expansion of both central as well as effector memory CD4
and CD8 T cell pools, elicitation of mainly Th1 memory response, reduction in the mycobacterial load and alleviated lung
pathology. Importantly, the protection induced by IM-1.6.a was significantly better than BCG. Thus, this study demonstrates
that not only antigen-pulsed DCs can be successfully employed as vaccines against cancer and infectious diseases but also
macrophages infected with M. tb can be utilized with great efficacy especially in protection against TB.
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Introduction
In 1992, nearly 100 million children received BCG [1]. Despite
the reality that more people have been immunized with BCG than
any other vaccine, TB continues to kill some 2 million people
annually and 2 billion people worldwide are infected with M. tb
[2]. Hence, the protective efficacy of the BCG vaccine remains
doubtful. The wide spread of TB has been further aggravated by
the emergence of multidrug-resistant (MDR) strains of mycobac-
teria and the AIDS-pandemic [3]. Therefore, there is a serious
need and challenge for scientific community to develop alternative
vaccines for the control of the disease.
Approximately one-third of the world population is infected with
M. tb, but only 5%–10% contract active disease while remaining
develop effective immunity [2]. Further, mice cleared of TB
infection respond vigorously upon re-exposure to mycobacteria and
remain protected [4]. This suggests that infection with viable
mycobacteria develop effective and long-lasting protective immu-
nity. There may exist a possibility that growing bacilli express
discrete molecules inside the macrophage [5], that may act as
protective antigens necessary for the generation of effector and
memory T cells responsible for protective immunity. Whether such
protective antigens of M. tb that can be exploited as vaccines, still
remains to be identified. [4,5]. Incidentally, the antigens isolated
from in vitro cultures have failed to generate considerable protective
immunity, corroborating to the above mentioned hypothesis [6,7].
In the past few decades, a number of new vaccine approaches
like naked DNA vaccines, live attenuated vaccines and subunit
vaccines have been elucidated. Unfortunately, none of them
worked successfully against TB since they failed to generate long-
lasting memory cells [8]. This indicates that novel and unique
vaccination strategies still need to be explored for TB.
Recently, many studies have highlighted the role of cell-based
vaccines viz. antigen-loaded DCs to evoke protective T cell
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wise, this also encouraged us to generate a vaccine by culturing live
M. tb in host macrophages. Our assumption that this approach
may be effective, stems from the fact that the bacterium in its
natural habitat (macrophages) is likely to secrete unique antigens
that may eventually help in generating protective immune
response [5]. The preparation was made safe for immunization,
by drug treatment [5]. Noteworthy observations obtained on
vaccination with the infected macrophages was that it augmented
T cell proliferation, IFN-c production and reduction in mycobac-
terial load, the parameters that are crucial for protection against
M. tb. This vaccination strategy worked successfully not only for
TB but also against S. typhimurium [5]. This study demonstrated
significant protection against both the intracellular pathogens in a
short-term study (30 days). However, no CD8 T cell responses
were examined and efficacy of vaccine was also not compared with
BCG. The vaccine failed to generate protective immunity in long-
term study (240 days).
Immunological memory can be enhanced by the use of selected
cytokines [12,13]. Hence, supplementing cytokines with vaccines
to bolster T cell memory can be an attractive approach. Role of
inflammatory and common c-chain cytokines has been highlighted
in the literature in enhancing T cell memory response. Cytokines
like IL-1, IL-6 and TNF-a help in the expansion and survival of
memory T cells [14,15] whereas common c-chain cytokines, IL-7
and IL-15 have dominant roles in generation and homeostasis of
memory T cells [12,16,17].
The present study was conducted to check whether vaccination
with M. tb infected macrophages supplemented with T cell
memory enhancing cytokines could generate enduring T cell
memory. We vaccinated mice with M. tb infected macrophages
vaccine with IL-1+IL-6+TNF-a (IM-1.6.a) and IL-7+IL-15 (IM-
7.15) to study the generation and sustenance of long-term (240
days) protective immunity against M. tb [18]. Interestingly, IM-1.6.
a demonstrated considerable augmentation in both CD4 and CD8
T cell memory pool, as evidenced by significant improvement in
immune response and protection against M. tb. Importantly, the
vaccine showed better efficacy than BCG and hence can be a
potent future vaccination strategy against TB.
Results
Vaccination with sIM-1.6.a elicits enduring Th1 response
Induction of long-lasting immunity is a cardinal feature of a
successful vaccine. Hence in the present study, we investigated how
enduring T cell memory can be elicited by M. tb infected syngeneic
macrophages (sIM). It is reported that combination of either IL-
1+IL-6+TNF-a or IL-7+IL-15 can induce long-term T cell memory
response [14,16,19]. Therefore, we co-administered these cytokines
with the vaccine and studied the sustenance of long-lasting memory
T cells. After vaccination, the mice were rested for sufficiently long-
duration (240 days) before challenge with M. tb, to establish bona fide
T cell memory response [18]. Interestingly, co-administration of IL-
1+IL-6+TNF-a with M. tb infected syngeneic macrophages (sIM-
1.6.a) considerably improved the immune response (Figure 1). The
T cell response observed with sIM-1.6.a immunization in response
to PPD (purified protein derivative from M. tb), was significantly
better than BCG (p=0.0253) and sIM alone (p=0.0176)
(Figure 1A). Cells obtained from the control groups inoculated
with PBS (110206643 cpm), uninfected syngeneic macrophages
(65136417 cpm), and 1.6.a alone (69816293 cpm) failed to
improve T cell response. Further, these results were substantiated
using two other M. tb antigens, short-term culture filtrate (STCF-
H37Rv) and infected macrophages cytosolic (IMC) antigenic
proteins (Figure S1A and Figure S2A). However, we did not
observe any change when IL-7 and IL-15 were administered along
with sIM (data not shown). Hence, subsequent experiments were
conducted with vaccine supplemented with IL-1+IL-6+TNF-a.
Th1 cells are known to play crucial role in protection against
TB [20]. Hence we next monitored the Th1 cytokines (IL-2 and
IFN-c) elicited by the vaccine. As compared to BCG and sIM,
vaccination with sIM-1.6.a showed predominance of Th1 immune
response as evident by significantly higher production of IFN-c
(p=0.0071; p=0.0071 respectively) and IL-2 (p=0.0057;
p=0.0052 respectively) on in vitro stimulation with either PPD
(Figure 1B, C) or STCF-H37Rv (Figure S1B, C) or IMC (Figure
S2B, C). It is a well established fact that B cells produce mainly
IgG2a and IgG1 on interaction with Th1 and Th2 cells
respectively [21]. Interestingly, we detected primarily M. tb specific
IgG2a-isotypes (BCG vs sIM-1.6.a, p=0.0037) (Figure 1D). This
further substantiates the predominance of Th1 response elicited by
sIM-1.6.a. Adaptive immune response is initiated in the local
lymph nodes, effectors subsequently migrate to the site of infection
[22,23,24]. Since the appearance of adaptive immunity in the
lungs play a seminal role in imparting protection against M. tb,i t
was imperative to monitor the local immunity as well. Like
lymphoid organs, mainly Th1 response was also observed in the
lymphocytes isolated from the lungs (Figure 1E, 1F; Figure S1D,
S1E; Figure S2D, S2E). No change was observed in the secretion
of IL-4 and IL-5 (Figure S3). The proliferation and cytokines data
signify that vaccination with sIM-1.6.a significantly evokes long-
lasting Th1 immunity against M. tb.
sIM-1.6.a induces enduring CD4 and CD8 T cell memory
response
We next monitored the expression of memory T cell markers
viz. CD44, CD62L and IL-7R (CD127), on the cells isolated
from spleen and lymph nodes of the immunized mice (Figure 2).
The cells were in vitro stimulated with PPD. sIM-1.6.a substantially
expanded pool of CD44 and IL-7R expressing CD4 T cells (13.1
vs 51.0%) compared to sIM vaccine (Figure 2A). Similar results
were exhibited by CD8 T cells (16.1 vs 41.5%) (Figure 2C).
Further, this observation was also supported by improvement in
the central (CD44
hi CD62L
hi) as well as effector (CD44
hi
CD62L
lo) memory T cells (Figure 2A–D). Enhancement in
total number of cells was also observed (Figure 2B, D). Overall
these findings specify that immunization with sIM-1.6.a can
induce long-lasting memory response in both CD4 and CD8 T
cells.
Vaccination with sIM-1.6.a imparts better protection than
BCG
sIM-1.6.a elicited enduring CD4 Th1 and CD8 T cell memory,
the parameters favorable for a successful TB vaccine. Hence, we
next checked the protective efficacy of sIM.1.6.a in M. tb aerosol
challenged mice. Interestingly, vaccination with sIM-1.6.a con-
siderably reduced the lung mycobacterial burden compared to
sIM (p=0.0004) and BCG (p=0.0067) (Figure 3A). Control
groups inoculated with placebo; PBS (log10 CFU 5.1760.16)
(Figure 3A), uninfected syngeneic macrophages alone (log10 CFU
5.3760.029), and 1.6.a alone (log10 CFU 4.6660.064) (Figure S4)
failed to show any significant decline in CFU (p.0.05 for PBS vs
1.6.a or uninfected syngeneic macrophages). Interestingly, neither
sIM-7.15 nor BCG-1.6.a could provide better protection than
controls syngeneic uninfected macrophages (sMac) or BCG
respectively (Figure S4). Further, protection imparted by sIM-
1.6.a vaccination was reflected by qualitative analysis of lungs
Infected Macrophages as Vaccine
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was observed with minimum lungs tissue involvement. In contrast,
mice inoculated with BCG and placebo (PBS) revealed granulo-
matous infiltrations with active TB lesions (Figure 3B).
Pragmatic approach to utilize IM-1.6.a
The requirement of syngeneic macrophages is a major concern
in extrapolating mice data for practical human application. We
showed earlier that vaccination with syngeneic, allogeneic and
xenogeneic macrophages infected with M. tb and S. typhimurium or
pulsed with ovalbumin could successfully mount an immune
response against the entrapped antigens [5,25]. Therefore we next
ascertained whether IL-1+IL-6+TNF-a with infected xenogeneic
(THP-1) macrophages (xIM-1.6.a) could provide similar outcome
as observed in the case of syngeneic infected macrophages (sIM-
1.6.a) (Figure 1, 2, 3). The cells isolated from spleen and lymph
nodes of the immunized mice were in vitro stimulated with PPD. As
observed in the case of sIM-1.6.a, similar pattern of enhancement
of T cell proliferation (p=0.004), IFN-c (p=0.0066), IL-2
(p=0.0046) and IgG2a (p=0.0317) secretion than control xIM
alone was observed with xIM-1.6.a (Figure 4A–D). Further, like
lymphoid organs, lymphocytes isolated from lungs also showed
significantly better yield of IFN-c (p=0.0355) and IL-2
(p=0.0164) (Figure 4E, F). Furthermore, no difference was
observed in the production of IL-4 and IL-5 (Figure S6). The
results were reproduced with all the tested antigenic preparations
(PPD, STCF-H37Rv) (Figure 4, Figure S5). Furthermore, like
sIM-1.6.a, augmentation in both central (CD44
hi CD62L
hi) and
effector (CD44
hi CD62L
lo) memory CD4 and CD8 T cells was
noticed on vaccination with xIM-1.6.a (Figure 5). Enhancement in
both percentage (Figure 5A, C) and total number of cells
(Figure 5B, D) was observed.
Lastly, we also checked the protective efficacy of xIM-1.6.a
against M. tb. Mice vaccinated with xIM-1.6.a showed significantly
better reduction in mycobacterial load in the lungs compared to
uninfected control xenogeneic macrophages (p=0.0015) and xIM
(p=0.0495) (Figure 6A) and its protective efficacy of was found to
be similar with that of sIM-1.6.a (Figure S7). Further, alleviated
Figure 1. sIM-1.6.a elicits a long-lasting Th1 immune response. Mice were vaccinated with sIM-1.6.a and sIM. After 240 days, they were
aerosol challenged with M. tb and were sacrificed 35 days later. Lymphocytes Pooled from spleen and lymphnodes of immunized mice were
stimulated in vitro with PPD (50 mg/ml) for 48 h. T cell proliferation was monitored by
3H-thymidine incorporation (A); secretion of IFN-c (B) and IL-2
(C) in the culture SNs by ELISA. Ratio of PPD specific IgG2a/IgG1 antibodies were estimated in serum (10006dilution) (D); production of IFN-c (E) and
IL-2 (F) was estimated in the culture SNs of lymphocytes isolated from lungs, in vitro stimulated with PPD (50 mg/ml). Data shown are mean 6 SEM
and representative of two experiments with n=3 animals per group. ‘*’, ‘**’ and ‘***’ indicate p,0.05, p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0016097.g001
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comparable with sIM-1.6.a vaccine (Figure 3A, B and Figure 6A,
B). These data very categorically establish that syngeneic
macrophage is not a pre-requisite for this vaccination strategy,
rather both syngeneic and xenogeneic macrophages can be
employed with equal efficiently.
Mechanism of priming of immune system by the vaccine
We hypothesize two possibilities which may explain generation
of immune response by the vaccine. Firstly, M. tb infected
syngeneic macrophages may directly present antigens to T cells.
Secondly, infected macrophages (syngeneic and xenogeneic) on c-
irradiation may undergo apoptosis [5,26] and resulting apoptotic
vesicles contain processed mycobacterial antigens [27,28]. These
apoptotic vesicles can be avidly taken up by Dendritic cells (DCs),
which then process and present antigens to CD4 T cells through
MHC-II or cross present to CD8 T cells via MHC-I pathway
[27,28]. Therefore to demonstrate the antigenic transfer by
apoptotic bodies to bystander DCs, Carboxyfluorescein diacetate
succinimidyl ester (CFSE)-labeled macrophages were infected with
Texas Red labeled M. tb (Figure 7A), followed by c-irradiation to
induce apoptosis [26]. This infected macrophage preparation was
in vitro co-cultured with bone marrow derived dendritic cells
(BMDCs). Interestingly, we observed the presence of apoptotic
vesicles containing mycobacterial antigens (orange fluorescence) in
DCs (Figure 7B), demonstrating that M. tb antigens from infected
macrophages can get transported to DCs. These DCs can then
process and present antigens to T cells and thereby imparting
optimum protection by eliciting immune response (Figure 1–6).
Discussion
Recently, cell based vaccines have gained considerable impetus
following their success against cancer [11]. We had earlier
demonstrated a novel strategy of vaccination by utilizing infected
macrophages [5]. This vaccination approach offered significant
protection not only against M. tb but also S. typhimurium [5].
However, it failed to induce long-lasting protection against M. tb.
Figure 2. sIM-1.6.a induces enduring CD4 and CD8 T cells memory response. Mice were immunized and aerosol challenged as mentioned
in Figure 1. Lymphocytes were stimulated in vitro with PPD (50 mg/ml) for 48 h and later stained with fluorochrome conjugated antibodies and
analyzed by flowcytometry. A, flow contours depict percentage of gated CD4 T cells expressing IL-7R and CD44 (upper panel); CD62L on CD4 T cells
(lower panel). C, gated CD8 T cells expressing IL-7R and CD44 (upper panel) and CD62L on CD8 T cells (lower panel). Bar diagrams show total number
of CD4 (B) and CD8 (D) T cells expressing CD44
hi, CD62L
hi and CD62L
lo. Data shown are mean 6 SEM of two independent experiments with n=3
animals per group. ‘*’ and ‘**’ indicate p,0.05 and p,0.01 respectively.
doi:10.1371/journal.pone.0016097.g002
Infected Macrophages as Vaccine
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elicit long-lasting memory. It is worth to mention here that even
though BCG successfully protects against the infant TB, it fails in
preventing the adult manifestation of the disease, reflecting poor
induction of long-lasting T cell memory [29]. Over the recent
years, studies have demonstrated a non-redundant role of
cytokines in differentiation and maintenance of memory T cells
[12,13]. Common c-chain and proinflammatory cytokines are
known to induce and support the persistent T cell memory
[12,14]. These cytokines act directly on both naive and memory T
cells and help in their survival and expansion [30]. Further, they
also assist in the recruitment of antigen presenting cells at the site
of vaccine administration.
Hence, in the light of above-mentioned facts, the present study
was conducted. We evaluated the role of co-administration of
common c-chain (IL-7+IL-15) or proinflammatory (IL-1+IL-
6+TNF-a) cytokines, with a cell based vaccine prepared using
macrophages infected with M. tb, in generating enduring T cell
memory and protection against TB. Mice were challenged with M.
tb after 240 days of vaccination to ensure the legitimate long-term
memory T cell responses [18]. The following major findings have
emerged from this study: IM-1.6.a significantly (i) inducted a
robust immune response that resulted in enduring memory CD4
and CD8 T cells; (ii) elicited a predominant Th1 immune
response; (iii) reduced mycobacterial load; (v) alleviated the lung
pathology; (vi) protected better than conventional BCG vaccine.
More than 90%–95% of the 2 billion individuals exposed to M.
tb never develop active disease [2], indicating that the bacillus
inhabiting the macrophages secretes unique molecules that
stimulate the immune system for efficient control of the disease.
Keeping this fact in the mind, we prepared a vaccine by infecting
macrophages with live M. tb simulating a natural scenario. The
preparation was made safe by killing the bacteria with isoniazid
and c-irradiated to induce apoptosis [5,26]. Interestingly,
incorporation of IL-1+IL-6+TNF-a with the vaccine significantly
enhanced enduring T cell memory response.
Although this approach effectively protected the immunized
mice from TB, the concern was its applicability to humans.
Preparing syngeneic macrophage vaccines for humans may not be
feasible. We had earlier demonstrated that major histocompati-
bility complex (MHC)–mismatched macrophages infected with
mycobacterium can also be used successfully for vaccination
[5,25]. Interestingly, co-administration of IL-1+IL-6+TNF-a with
xenogeneic vaccine (xIM-1.6.a) also elicited long-term immunity
against M. tb and response was comparable to sIM-1.6.a (Figure
S7).
We have also demonstrated the proof of principle of how this
vaccine may eventually prime the immune system. Apoptotic
bodies are likely to be generated by the infected macrophage
vaccine. Such apoptotic bodies could be avidly taken up in vivo by
DCs. Interestingly, we could locate apoptotic bodies loaded with
mycobacterial antigens inside the DCs (Figure 7). Further, DCs
but not macrophages can cross-present antigen of apoptotic cells
to T cells because they express avb5 integrin, which plays a critical
role in the trafficking of exogenous antigens [31,32]. Hence, DCs
that have phagocytosed apoptotic bodies containing mycobacterial
antigens are likely to prime both naı ¨ve CD4 T cells (via exogenous
pathway) and CD8 T cells (via cross presentation) to generate
Figure 3. sIM-1.6.a provides significantly better protection than BCG. Mice were immunized and aerosol challenged as mentioned in
Figure 1. Mycobacterial load in the lungs was enumerated by CFU plating of diluted lung homogenates. A, data are represented as log10 CFU (n=6
animals/group) where each triangle indicates single mouse. B, photomicrographs (106) of formalin fixed lungs sections stained with H & E. ‘+’
indicates active TB lesion with edematous follicular reaction while ‘R’ shows small or large developing follicular granulomas. Data are representative
of two independent experiments. ‘**’ and ‘***’indicate p,0.01 and p,0.001 respectively.
doi:10.1371/journal.pone.0016097.g003
Infected Macrophages as Vaccine
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16097protective immune response against M. tb. Furthermore, as DCs
secrete IL-12, they are capable of skewing immune response
towards IFN-c secreting CD4 and CD8 T cells [33]. The
proinflammatory stimuli is also necessary for diverting the immune
response towards protective Th17 cells, which is reported to be
important for the rapid recruitment of Th1 effectors to the lungs
[34,35]. Moreover, DCs trap foreign antigen (in this case
mycobacterium antigen) and act as reservoir, slowly releasing the
antigen in the system for the activation of T cells and maintenance
of memory cells [36]. Hence, incorporating IL-1+IL-6+TNF-a
with vaccine, promotes the generation of long-term memory T
cells.
Based on our findings, we envisage that the strategy of utilizing
MHC-mismatched macrophages can work as a promiscuous
vaccine for humans. Importantly, the preparation requires no
adjuvant and shows better protection than BCG. Therefore, we
conclude that IM-1.6.a may be a possible vaccine candidate
against TB, based on its uniqueness of utilizing novel antigens
(secreted within the natural environment of the macrophages
which may be of paramount importance for evoking protection)
and presence of IL-1+IL-6+TNF-a (for induction and sustenance
of enduring CD4 and CD8 T cell memory responses).
Materials and Methods
Experimental animals
BALB/c mice (female, 6–8 weeks old) were procured from
National Institute of Pharmacological Education and Research,
Mohali, India and National Institute of Immunology, New Delhi,
India. Animals were kept in Biosafety Level-3 facility of Institute of
Microbial Technology (IMT), Chandigarh, India and National
JALMA Institute for Leprosy and Other Mycobacterial Diseases
Figure 4. Vaccination with xIM-1.6.a evokes immune response. Mice were vaccinated with xIM-1.6.a with similar immunization protocol as
mentioned in Figure 1. Lymphocytes pooled from spleen and lymphnodes of immunized animals were stimulated in vitro with PPD (50 mg/ml) for
48 h and later T cell proliferation was monitored by
3H-thymidine incorporation (A); secretion of IFN-c (B) and IL-2 (C) in culture SNs; PPD specific
IgG2a/IgG1 antibodies in the serum (10006dilution) (D) were estimated by ELISA. Production of IFN-c (E) and IL-2 (F) was estimated in the culture
SNs of the lymphocytes isolated from lungs, in vitro stimulated with PPD (50 mg/ml). Data shown as mean 6 SEM are representative of two
experiments, n=3 animals per group. ‘*’ and ‘**’ indicate p,0.05 and p,0.01 respectively.
doi:10.1371/journal.pone.0016097.g004
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and water ad libitum.
Ethics Statement
All animal experiments were approved by the Institutional
Animal Ethics Committees of IMT and NJIL&OMD. All animal
experiments were performed according to the National Regulatory
Guidelines issued by CPSEA (Committee for the Purpose of
Supervision of Experiments on Animals), Ministry of Environment
and Forest, Govt. of India.
Reagents and antibodies
Middlebrook 7H9, 7H11, ADC and OADC were procured from
Difco Laboratories (Sparks, MD). Recombinant mouse IL-1, IL-6,
TNF-a, IL-7 and IL-15 from Peprotech (Rocky Hill, NJ).
Fluorochrome labeled anti-mouse antibodies, FITC-conjugated
CD4 (H129.19), IgG2a isotype control (R35-95); PE-conjugated
CD62L (MEL-14), IgG2b isotype control (R35-95), IgG2c isotype
control (A23-1); PE-Cy5-conjugated CD44 (IM7), Sv-PE-Cy5;
Pacific Blue conjugated CD4 and IgG2a isotype control (R35-95);
APC-Cy7-conjugatedCD8(53-6.7)andIgG2aisotypecontrol(R35-
95); biotin-conjugated CD4 (H129.19) and IgG2a isotype control
(R35-95)andpairmatchedantibodiesforELISA,JES6-1A12,JES6-
5H4 (IL-2); 11B11, BVD6-24G2 (IL-4); TRFK5, TRFK4 (IL-5);
R4-6A2, XMG1.2 (IFN-c), A85-1 (IgG1-Biotin), R19-15 (IgG2a-
biotin) procured from BD Biosciences (San Diego, CA). FITC-
conjugated CD8 (KT15) and IgG2a isotype control were from AbD
Serotec (Langford Lane, Kidlington, UK). Tissue culture grade
plastic-wares were purchased from BD Biosciences (Bedford, MA)
and Nunc (Rochester, NY). Texas Red succinimidyl ester was
procuredfromInvitrogen(Eugene,OR).All otherstandardreagents
were purchased from Sigma (St. Louis, MO) unless mentioned.
Figure 5. Vaccination with xIM-1.6.a induces CD4 and CD8 T cells memory response. Mice were immunized and aerosol challenged as
mentioned in Figure 1. Pooled lymphocytes from spleen and lymphnodes of immunized animals were stimulated in vitro with PPD (50 mg/ml) for
48 h and later stained with fluorochrome tagged antibodies and analyzed by flowcytometry. A, flow contours depict percentage of CD4 T cells
expressing IL-7R and CD44 (upper panel); CD62L expression on CD4 T cells (lower panel). C, CD8 T cells expressing IL-7R and CD44 (upper panel);
CD62L on CD8 T cells (lower panel). Bar diagrams show total number of CD4 (B) and CD8 (D) T cells expressing CD44
hi, CD62L
hi and CD62L
lo. Data
shown are mean 6 SEM of two independent experiments with n=3 animals per group. ‘*’ indicates p,0.05.
doi:10.1371/journal.pone.0016097.g005
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M. tb H37Rv and M. bovis BCG (Danish strain) were kind gifts
from Dr. V. M. Katoch, NJIL&OMD, Agra. Mycobacteria were
cultured in 7H9 medium containing 0.05% Tween80 supple-
mented with 10% ADC enrichment. Short term culture filtrates
(STCF) and purified protein derivative (PPD) were prepared by
standard protocols [19]. Briefly, the mycobacteria from log
phage cultures were grown in 7H9 broth without ADC
enrichment and Tween80 for 2 weeks at 37uC. The culture
supernatant was harvested by centrifugation and filtered through
0.2 mm membrane filter. Supernatant containing culture filtrate
proteins were lyophilized. Lyophilized proteins were dissolved
and dialyzed extensively against PBS and stored at 280uCf o r
future use. For PPD preparation, cultures were incubated for 8–
9 weeks at 37uC. Later, cultures were autoclaved at 121uCf o r
30 min and cooled overnight at room temperature. Bacterial
cells were removed by centrifugation followed by filtration. The
proteins in the filtrate were precipitated by trichloroacetic acid
(4% final concentration) by keeping overnight at room
temperature without any agitation. Later, the precipitate was
centrifuged at 25006g for 15 min to remove supernatant. The
precipitate was washed 26 with 1% TCA and once with 10%
NaCl. Then precipitate was dissolved in PBS, filter sterilized and
stored at 280uC for future use.
Cells and cell lines
Peritoneal macrophages. Mice were inoculated with 3 ml
of 3% thioglycollate medium intraperitoneally. After 96 h,
peritoneal exudates cells (PECs) were harvested and washed 26
with RPMI-1640-FBS-1%. Macrophages were purified by
adhering on 90 mm tissue culture dish for 2 h.
THP-1. A human macrophage cell line was maintained in
RPMI-1640-FBS-5% and used as source of xenogeneic
macrophages for vaccine preparation.
Bone marrow derived dendritic cells (BMDC). Bone
marrow cells were isolated from femur of BALB/c mice and
cultured (2610
6) in 60 mm Petri dish in the presence of GM-CSF
(10 ng/ml) and IL-4 (5 ng/ml) in complete RPMI-1640-FBS-10%
for 6 days. Cultures were replenished with fresh GM-CSF and IL-
4 after 3 days. Cells were harvested on day 7 for experiments.
Preparation of infected macrophages and cytosolic
antigenic proteins
Infected syngeneic (sIM) and xenogeneic (xIM) macrophage
vaccines for immunization and infected macrophages cytosolic
(IMC) antigenic proteins for in vitro studies were prepared by
culturing live M. tb inside the macrophages as described earlier [5].
Briefly, syngeneic peritoneal macrophages and xenogeneic THP-1
cells were plated overnight at 37uC in antibiotic free RPMI 1640-
Figure 6. Immunization with xIM-1.6.a provides protection against M. tb. Mice vaccinated with xIM-1.6.a were rested for 240 days and then
aerosol challenged with M. tb. After 35 days, mice were sacrificed and mycobacterial load was enumerated by CFU plating of diluted lung
homogenates. A, data are represented as log10 CFU (n=4–6 animals/group). B, photomicrographs (106) of H & E stained lungs sections. Control
groups of mice were inoculated with uninfected xenogeneic macrophages (xMac). Data are mean 6 SEM of two independent experiments, where
‘*’ and ‘**’ indicate p,0.05 and p,0.01 respectively.
doi:10.1371/journal.pone.0016097.g006
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for 4 h. Extracellular bacteria were removed by extensive washing
with PBS. Infected cells were cultured with amikacin (50 mg/ml)
for 48 h to check residual extracellular bacteria, if any. Isoniazid
(100 mg/ml) treatment was given for next 48 h to kill intracellular
bacteria. The cells were harvested and c-irradiated (5000 rad).
The cells were washed 26and resuspended at a concentration of
5610
6 cells/ml in PBS. For preparation of IMC, infected
macrophages were lysed in a buffer containing 10 nmol/L Tris
(pH 8.0), 1% Triton X-100, 150 nmol/L NaCl, 5 mmol/L
EDTA, 1 mmol PMSF, 10 mg/L aprotinin and 10 mg/L
leupeptin. Disrupted cells were centrifuged at 6006g for 20 min,
supernatant was collected and ultracentrifuged at 100,0006g for
1 h at 4uC. Supernatant was then dialyzed extensively against PBS
and stored at 280uC for future use.
Immunization
Syngeneic (sIM) or xenogeneic (xIM) infected macrophages
vaccine (5610
5 macrophages/100 ml PBS/mouse) alone or along
with recombinant IL-1, IL-6 (500 ng/mouse, each cytokine) and
TNF-a (250 ng/mouse) (IM-1.6.a) or IL-7 and IL-15 (500 ng/
mouse, each cytokine) (IM-7.15) were injected intraperitoneally.
After 21 days, booster dose of same preparation was given. Control
mice were administered with placebo (PBS or 1.6.a alone), BCG
and BCG-1.6.a. To establish a bona fide memory response, animals
were rested for 240 days before aerosol challenge [18].
Aerosol infection and determination of mycobacterium
burden
Mice were infected with a low dose aerosol challenge with M. tb
to deposit approximately 100 bacteria/lung using an inhalation
exposure system (Glas-Col, Terre Haute, IN) [19]. Briefly, animals
were exposed to M. tb aerosol for 45 min with a standardized dose.
Numbers of mycobacteria deposited were determined by plating
total lung homogenates on Middlebrook 7H11 plates supplement-
ed with OADC enrichment within 24 h. The mycobacterium
burden in the immunized animals was determined after 35 days of
aerosol challenge by plating serially diluted homogenates of
individual lung. CFUs were counted after 3–4 weeks of incubation
at 37uC and total load of lung tissue was expressed as log10 CFU.
Isolation of lymphocytes from spleen, lymph nodes and
lungs
Mice were sacrificed after 35 days of aerosol challenge with M. tb.
A single cell suspension from spleen, lymph nodes (inguinal, axillary
Figure 7. Apoptotic bodies generated by IM transport antigen to bystander dendritic cells. M. tb infected macrophages were co-cultured
with Dendritic cells (DCs) for 48 h. Later, fluorescence microscopy was used to demonstrate generation of apoptotic bodies containing mycobacterial
antigens and their uptake by bystander DCs. (A) Left panel, arrows indicate Texas Red labeled M. tb; Middle panel, M. tb infected macrophages
(orange, mixed fluorescence) and asterisks depict uninfected macrophages (green); right panel, DIC image of macrophages (images at 1006). (B) Left
panel, arrows indicate Texas Red labeled M. tb; middle panel, arrows indicate M. tb within apoptotic bodies (orange, mixed fluorescence) while
asterisks indicate apoptotic bodies (green) devoid of mycobacteria; right panel, DIC image of DCs show engulfment of apoptotic bodies containing
mycobacterial antigens by DCs (Images at 10061.66). Arrow heads indicate association of apoptotic macrophages with DCs. DIC, Differential
interference contrast. () Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016097.g007
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Briefly, lymphocytes from spleen were prepared by RBCs lysis with
ACK (NH4Cl 0.15 M, KHCO3 10 mM and EDTA 88 mM) buffer,
washed 36 with PBS and resuspended in RPMI-1640-FBS-10%.
For lymphocytes from lungs, perfused lungs were minced and
digested with collagenase (0.7 mg/ml) and DNase (30 mg/ml) at
37uC for 1 h. Digested lungs were disrupted gently by passage
through a 70-mm pore size cell strainers; residual RBCs, if any, were
lysed by ACK buffer. The resultant single cell suspension was
washed 36and resuspended in RPMI-1640-FBS-10%. Viable cells
were counted by trypan blue dye exclusion method.
Proliferation assays
Lymphoproliferation assays were set as described previously
[5,19]. Briefly, lymphocytes isolated from lymphoid (spleen and
lymph nodes) and non-lymphoid (perfused lungs) organs of mice
(2610
5 cells/well) were cultured in round-bottom 96-well plates, in
200 ml of RPMI-1640-FBS-10% and different concentrations
(1.56–50 mg/ml) of mycobacterial antigens (PPD, STCF-H37Rv,
IMC) for 48 h and 72 h respectively. Cells cultured with the
medium alone (without antigens) were used as controls. Later,
cultures were pulsed with 0.5 mCi of
3H-thymidine (Amersham
Pharmacia Biotech, Buckinghamshire, UK). The plates were
harvested after 16 h onto glass-fiber filter mats using a Tomtec-
Harvester-96 (Tomtec, Hamden, CT). Radioactivity incorporated
was measured using liquid scintillation spectroscopy by Wallac-
1450 Microbeta Trilux (Perkin Elmer, Waltham, MA).
Cytokines ELISA
Cultures were set as described in case of proliferation assays.
The culture supernatants (SNs) from the experimental and control
wells were collected after 24 h for IL-2 and 48 h for IL-4, IL-5 and
IFN-c estimation. Cytokines were estimated by sandwich ELISA
following manufacturer’s instructions [5,19]. The levels of
cytokines were calculated using standard recombinant cytokines
and expressed as pg/ml.
IgG isotypes ELISA
Serum samples were collected from clotted blood after 35 days
of aerosol challenge. M. tb specific antibodies were determined in
the serum of vaccinated mice, as described elsewhere [5,19].
Briefly, diluted serum samples (10006) were added on PPD
(10 mg/ml) coated plates. PPD specific antibodies were captured
by secondary biotinylated anti-mouse IgG1/IgG2a followed by
avidin-HRP/OPD-H2O2 step for colorimetric estimation. Usual
steps of washings and incubations were followed at each step.
Results were expressed as ratio of IgG2a to IgG1.
Staining for T cell memory surface markers
Cells were stimulated with antigens as described for prolifera-
tion assays. After 48 h of cultures, cells were stained for surface
memory markers[19]. Briefly, cells were harvested and washed 26
with staining buffer (PBS-FBS-1%). Cells were incubated with
2.4G2 antibodies to block Fc-receptors and stained with anti-
mouse fluorochrome labeled monoclonal antibodies (mAbs) (CD4,
CD8, CD44, CD62L, CD127 and isotype controls) for 30 min at
4uC. When staining with biotinylated antibodies, cells were
incubated with biotin conjugated mAbs for 30 min at 4uC
followed by incubation with secondary reagents (streptavidin-PE-
Cy5 or APC). Usual steps of washing and incubation were
followed at each interval. Finally, cells were fixed in 1%
paraformaldehyde. The cytometry data were acquired using
FACS Calibur and FACS Aria II (BD Biosciences, San Jose,
CA). Data were analyzed by DIVA software (BD Biosciences, San
Jose, CA). Total number of cells of a definite phenotype of CD4
+
and CD8
+ T cells (CD44
hi, CD62L
hi/lo) was calculated by taking
the percentage of gated cell type, as determined by flowcytometry,
multiplied by the total number of cells [22].
Histo-pathological analysis
Mice were sacrificed and lung tissues were fixed in 10%
buffered formalin. Histological sections were stained using
hematoxylin and eosin. Photomicrographs were captured on
Olympus IX71 microscope.
Engulfment of apoptotic bodies by Dendritic cells
Mycobacteria were stained with Texas Red as per manufac-
turer’s instructions. Briefly, single cell suspension of M. tb were
incubated with Texas Red (50 mg/ml) at room temperature for 2 h
followed by washing 56 to remove excess of stain. Peritoneal
exudate cells (PECs) were incubated with 3 mM of Carboxyfluor-
escein diacetate succinimidyl ester (CFSE) in PBS for 8 min at
37uC. Excess of CFSE was removed by treating with 100% FBS
and followed by washing 36with RPMI-FBS-10%. CFSE labeled
macrophages were purified by adhering on 90 mm tissue culture
dish for 2 h. Non adhered cells were removed by washings with
PBS. Adhered macrophages were infected with Texas Red stained
M. tb (MOI, 1:20) for 4 h. Extracellular bacteria were removed by
extensive washings with PBS. Infected macrophages were
harvested and washed 26with PBS-FBS-1% and subjected to c-
irradiation to induce apoptosis [26]. BMDCs (2610
5 cells/200 ml)
were adhered on glass cover slips for 4 h, followed by 36washing
to remove unattached cells. Gamma irradiated M. tb infected
macrophages were co-cultured with BMDCs on glass cover slips in
1:1 ratio for 48 h. Later, cover slips were washed 56with PBS and
fixed with 4% paraformaldehyde. Fluorescence images were
captured on Olympus IX71 microscope.
Statistical analysis
Data were analyzed by one way analysis of variance (ANOVA)
with post Tukey-Kramer multiple comparisons test. In case of
significant difference, absolute ‘p’ values for comparison between
two groups were calculated by Student’s‘t’ test using InStat 3
software (GraphPad).
Supporting Information
Figure S1 sIM-1.6.a exhibits a long-lasting Th1 immune
response on in vitro stimulation with STCF-H37Rv. Mice
were vaccinated with sIM-1.6.a. After 240 days, they were aerosol
challengedwithM.tband35dayslaterweresacrificed.Lymphocytes
Pooled from spleen and lymphnodes (A, B, C) and lungs (D, E) of
immunized mice were stimulated in vitro with STCF-H37Rv (50 mg/
ml). T cell proliferation was monitored by
3H-thymidine incorpo-
ration (A); secretion of IFN-c (B, D) and IL-2 (C, E) by ELISA in the
culture SNs. The control groups were administered with PBS, BCG
and sIM.Dataare shown asmean 6 SEM and representativeof two
experiments, n=3 animals per group. ‘*’, ‘**’and ‘***’ indicate
p,0.05, p,0.01 and p,0.001 respectively.
(TIF)
Figure S2 sIM-1.6.a demonstrates a long-lasting Th1
immune response against IMC. Mice were vaccinated as
mentioned in Figure S1. Lymphocytes Pooled from spleens and
lymph nodes (B, C) and lungs (D, E) were stimulated in vitro with
IMC (50 mg/ml). T cell proliferation was monitored by
3H-
thymidine incorporation (A); production of IFN-c (B, D) and IL-2
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administered with PBS, BCG and sIM. Data are shown as mean
6 SEM and representative of two experiments, n=3 animals per
group. ‘*’ and ‘**’ indicate p,0.05 and p,0.01 respectively.
(TIF)
Figure S3 sIM-1.6.a does not increase Th2 response.
Mice were vaccinated as mentioned in Figure S1. Lymphocytes
Pooled from spleens and lymph nodes (A) and lungs (B) were
stimulated in vitro with PPD, STCF-H37Rv and IMC (50 mg/ml).
Secretion of IL-4 and IL-5 was monitored in the culture SNs. The
control groups were administered with PBS, BCG and sIM. Data
are shown as mean 6 SEM and representative of two experiments,
n=3 animals per group.
(TIF)
Figure S4 sIM-7.15 and BCG-1.6.a failed to show any
protection. sIM-7.15 and BCG-1.6.a vaccinated mice were
rested for 240 days before aerosol challenge. After 35 days,
animals were sacrificed; mycobacterial load was enumerated by
CFU plating. Control groups were immunized with syngeneic
uninfected macrophages (sMac), BCG and cytokines alone (1.6.a
and 7.15). Data are represented as mean 6 SEM of log10 CFU
(n=4–5 animals/group) of two independent experiments.
(TIF)
Figure S5 Immunization with xIM-1.6.a also elicits
robust immune response against STCF-H37Rv. Mice
were vaccinated with xIM-1.6.a and xIM. After 240 days, they
were aerosol challenged with M. tb and 35 days later were
sacrificed. Lymphocytes Pooled from spleens and lymph nodes (A,
B, C) and lungs (D, E) were stimulated in vitro with STCF-H37Rv
(50 mg/ml). T cell proliferation was monitored by
3H-thymidine
incorporation (A); release of IFN-c (B, D) and IL-2 (C, E) in the
culture SNs by ELISA. Data are shown as mean 6 SEM and
representative of two experiments, n=3 animals per group. ‘*’ and
‘**’ indicate p,0.05 and p,0.01 respectively.
(TIF)
Figure S6 xIM-1.6.a does not augment Th2 response.
Mice were vaccinated as mentioned in Figure S5. Lymphocytes
pooled from spleens and lymph nodes (A) and lungs (B) were
stimulated in vitro with PPD and STCF-H37Rv (50 mg/ml).
Secretion of IL-4 and IL-5 was estimated in the culture SNs.
Data are shown as mean 6 SEM and representative of two
experiments, n=3 animals per group.
(TIF)
Figure S7 sIM-1.6.a and xIM-1.6.a provides compara-
ble protection against M. tb. Mice were vaccinated with sIM-
1.6.a and xIM-1.6.a and rested for 240 days before aerosol
challenge with M. tb. After 35 days, mice were sacrificed and
mycobacterial load was enumerated by CFU plating of diluted
lung homogenates. Control groups were inoculated with PBS and
BCG. Data are represented as mean 6 SEM of log10 CFU (n=4–
5 animals/group) of two independent experiments. ‘ns’, ‘*’, ‘**’and
‘***’ indicate non-significant, p,0.05, p,0.01 and p,0.001
respectively.
(TIF)
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